Combining Interferon-Beta and Temozolomide for Recurrent Anaplastic Astrocytoma
Author Information
Author(s): Fujimaki Takamitsu, Ishii Hisato, Matsuno Akira, Arai Hajime, Nakagomi Tadayoshi
Primary Institution: Teikyo University School of Medicine
Hypothesis
Can interferon-beta enhance the effectiveness of temozolomide in treating TMZ-refractory recurrent anaplastic astrocytoma?
Conclusion
The combination of interferon-beta and temozolomide was effective in treating a patient with TMZ-refractory recurrent anaplastic astrocytoma.
Supporting Evidence
- The tumor decreased in size by 50% after the second treatment cycle.
- The patient's Karnofsky performance status improved from 70% to 100%.
- Interferon-beta was reported to suppress MGMT, which is linked to drug resistance.
Takeaway
Doctors tried a new treatment using two medicines to help a patient whose brain tumor didn't get better with the usual medicine. It worked and made the tumor smaller.
Methodology
The patient was treated with interferon-beta followed by temozolomide in cycles, and their tumor response was monitored through MRI.
Limitations
The study is based on a single case report, limiting generalizability.
Participant Demographics
A 51-year-old male patient with recurrent anaplastic astrocytoma.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website